Comparison
AOD-9604 vs. CJC-1295
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
221231-10-3
no data
Molecular weight
1815.09 g/mol
3647.3 g/mol
Half-life
0.4 h
144 h
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheYADAIFTNSYRKVLGQLSARKLLQDIMSR-DACMechanism of action
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
3
3
of which in humans
2
2
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
3